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Abstract
Reprogramming somatic cells into a pluripotent state brings 
patient-tailored, ethical controversy-free cellular therapy 
closer to reality. However, stem cells and cancer cells share 
many common characteristics; therefore, it is crucial to 
be able to discriminate between them. We generated two 
induced pluripotent stem cell (iPSC) lines, with NANOG 
pre-transduction followed by OCT3/4, SOX2, and LIN28 
overexpression. One of the cell lines, CHiPS W, showed 
normal pluripotent stem cell characteristics, while the other, 
CHiPS A, though expressing pluripotency markers, failed 
to differentiate and gave rise to germ cell-like tumours in 
vivo. Comparative genomic hybridisation analysis of the 
generated iPS lines revealed that they were genetically 
more stable than human embryonic stem cell counterparts. 
This analysis proved to be predictive for the differentiation 
potential of analysed cells. Moreover, the CHiPS A line 
expressed a lower ratio of p53/p21 when compared to 
CHiPS W. NANOG pre-induction followed by OCT3/4, 
SOX2, MYC, and KLF4 induction resulted in the same 
tumour-inducing phenotype. These results underline the 
importance of a re-examination of the role of NANOG 
during reprogramming. Moreover, this reprogramming 
method may provide insights into primordial cell tumour 
formation and cancer stem cell transformation.
Keywords: Induced pluripotent stem cells, stem cells, 
cancer stem cells, NANOG, cancer, germ-cell tumour, 
reprogramming, pluripotency.
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Introduction
Pluripotent stem cells have attracted much attention 
from the scientifi c community in recent years. They 
hold promise for various therapeutic applications, from 
regenerative therapies to pharmacological screening. 
Technical diffi culties and ethical issues associated with the 
isolation of adult or embryonic stem cells have redirected 
interest towards induced pluripotent stem cells (iPSCs). 
Obtained from lineage-specifi c cells via reprogramming 
with a maximum of four reprogramming genes (RGs), 
POU5F1 (OCT3/4), SOX2 and MYC, KLF4, or NANOG 
and LIN28 (Takahashi et al., 2007; Yu et al., 2007), 
iPSCs seem to be a very promising area for future stem 
cell research. Despite obvious advantages such as donor 
compatibility and an unlimited supply, there are still 
numerous challenges to be met before iPSCs become 
routinely used in regenerative medicine or standardised for 
patient-specifi c drug research (reviewed in: Stadtfeld and 
Hochedlinger, 2010). One major obstacle is the capability 
of pluripotent stem cells to form tumours in vivo. At fi rst, 
human embryonic stem cells (hESC) were believed to 
produce only benign teratomas; however, recent studies 
have demonstrated that hESC lines can also develop 
malignant features after being kept in culture (Hovatta 
et al., 2010; reviewed in: Blum and Benvenisty, 2009).
 There is increasing evidence of the existence of a 
distinct cell sub-population within a tumour, called cancer 
stem cells (CSCs), which shares many characteristics 
with normal stem cells (Bonnet and Dick, 1997). CSCs 
are believed to be responsible for the tumour’s ability 
to undergo epithelial-mesenchymal transition (EMT), 
and may play a role in relapse, metastasis, and treatment 
resistance (reviewed in: Bomken et al., 2010; Tysnes, 
2010). It remains controversial as to whether CSCs 
originate from stem cells that have undergone aberrant 
transformation or from terminally differentiated cells 
that have reversed their cellular program. Very limited 
evidence indicates that normal stem cells and cancer stem 
cells differ (Guzman et al., 2005; Yilmaz et al., 2006). 
Therefore, it is crucial to understand the carcinogenic 
aspect of stem cells before they can be implemented 
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therapeutically. Thus, research towards fi nding ways to 
limit the tumour formation risk of iPSC, for instance 
by developing strategies allowing accurate sorting of 
potentially carcinogenic cells, is essential. In the present 
study, we generated and analysed two iPSC lines. One 
of the lines, the CHiPS W, displayed normal pluripotent 
stem cell characteristics and gave rise to a teratoma 
expressing components of the three germ layers during an 
in vivo differentiation assay. The other line, the CHiPS A, 
despite its iPSC-like morphology and marker expression, 
resulted in germ cell-like tumours when injected into 
immunoincompetent mice. The analysis of OCT3/4 and 
NANOG expression and the methylation status of their 
promoters showed their re-activation in the CHiPS A 
line. Since it has been previously demonstrated that 
genomic instability in hESC lines might lead to neoplastic 
progression (Werbowetski-Ogilvie et al., 2009), we used 
comparative genomic hybridisation and single nucleotide 
polymorphism assays to detect genomic signatures in 
the derived iPSC lines. We also estimated the relative 
expression of TP53 (p53) and CDKN1A (p21) in both lines. 
Finally, we showed that the resulting NANOG-induced 
tumourigenic phenotype is independent of the other RGs 
used. These results underline the importance of a re-
examination of the role of NANOG during reprogramming 
and the need for detailed iPSC characterisation prior to 
clinical use. Moreover, as the generated lines were derived 
from a uniform genetic background, they may serve as a 
model of cancer stem cell formation.
Materials  and Methods
Cell lines
The hESC line H1 came from the WiCell Research Institute 
(Madison, WI, USA). HS401 was derived as previously 
described (Inzunza et al. 2005; Ström et al., 2010). iPSC 
lines were derived as follows: the CHiPS A line was derived 
by transducing 50,000 human fi broblasts (ATCC, CRL-
2429) with 5 MOI of pSin-EF2-Nanog-Pur. After 24 h, cells 
were re-transduced with three viruses (MOI 5): pSin-EF2-
Sox2-Pur, pSin-EF2-Oct4-Pur, and pSin-EF2-Lin28-Pur 
(kindly donated by J.A. Thomson). The CHiPS W line was 
derived by transducing 50,000 human fi broblasts with 5 
MOI of pSin-EF2-Nanog-Pur. The cells were treated with 
puromycin for 5 days to select for transformed cells and 
then re-transduced with three viruses: pSin-EF2-Sox2-Pur, 
pSin-EF2-Oct4-Pur, and pSin-EF2-Lin28-Pur (MOI 5). 
The CHiPS 22 line was derived by fi rst transducing 50,000 
human fi broblasts with 5 MOI of pSin-EF2-Nanog-Pur; 
after 24 h, cells were re-transduced with the Stem Cell 
Cassette (STEMCCA) polycistronic lentiviral vector, 
carrying the four Yamanaka RGs (Sommer et al., 2009) 
(kindly donated by G. Mostoslavsky). All iPSC and hESC 
lines were cultured on irradiated human foreskin fi broblasts 
and passaged mechanically. Cells were grown in iPSC 
medium: Knockout Dulbecco’s Minimal Essential Medium 
(DMEM) supplemented with 20 % Serum Replacement, 2 
mmol/L Glutamax, 40 μg/mL gentamycin and 100 μmol/L 
β-mercaptoethanol (all Gibco/Invitrogen, Carlsbad, CA, 
USA). For the H1 cell line, medium was supplemented 
with 10 ng/mL bFGF (fi broblast growth factor). All iPSC 
lines were initially cultured according to the protocol 
established by Thomson’s group (Yu et al., 2007), and 
supplemented with 100 ng/mL bFGF; however, the CHiPS 
22 and CHiPS A lines grew robustly, so we decided to lower 
the concentration of bFGF to 10 ng/mL for those lines to 
decrease the cost of culture. To exclude the infl uence of 
the different bFGF concentrations on the experimental 
results, prior to DNA, RNA or protein extraction, cells were 
cultured for one passage (at least 48 h) under feeder-free 
culture conditions on Matrigel (Becton Dickinson AG, 
Basel, Switzerland) coated plates in NutriStem medium 
(Stemgent, Cambridge, MA, USA) supplemented with 10 
ng/mL bFGF. Matrigel was diluted 1:30 with KO DMEM 
and after plating allowed to gel at room temperature for 1 
h before use. The fi broblast feeders (ATCC, Manassas, VA, 
USA; CRL-2429) were cultured in IMDM supplemented 
with 10 % foetal calf serum, 2 mmol/L Glutamax and 1 
% penicillin/streptomycin (all Gibco/Invitrogen). Feeder 
cells were mitotically inactivated by irradiation at 35 Gy 
before seeding on a gelatin-coated 35 mm dish at 3.5×105 
cells/dish. The iPSC and hESC culture medium was 
changed daily.
Immunohistochemistry
Cells were passaged manually onto a GFP-positive 
feeder layer (Unger et al., 2009). After fixation in 4 
% formaldehyde, they were washed three times with 
phosphate buffered saline (PBS), blocked with 1 % 
bovine serum albumin (BSA) and stained with antibodies 
against OCT3/4 (Santa Cruz Laboratories, Santa Cruz, 
CA, USA; sc-5279), NANOG (Santa Cruz Laboratories, 
sc-33759), TRA-1-60 (Santa Cruz Laboratories, sc-
21705), and SSEA4 (Santa Cruz Laboratories, sc-21704) 
overnight at 4 °C. After three washes with PBS, cells 
were incubated with fl uorescent probe-labelled secondary 
antibodies and mounted with UltraCruz™ Mounting 
Medium containing DAPI. Ki-67 immunostaining was 
performed as follows: after standard deparaffi nisation, 
antigen retrieval was performed with 0.01 M citrate (pH 
6) at 100 °C. Endogenous peroxidase was blocked with 
HP-Blocking solution (S2023; Dako, Glostrup, Denmark) 
and the slides were incubated with a Ki-67 antibody (mib1, 
Dako, M7240). Secondary antibody incubation and signal 
development was performed in DAB solution according to 
the manufacturer’s instruction (Dako). All staining were 
performed three times independently.
Karyotype
Karyotyping was performed in at least twenty metaphase 
spreads, using the GTG-banding method, by an independent 
laboratory (Genetic Service, Geneva University Hospitals, 
Switzerland). Briefly, iPSCs were incubated in iPSC 
medium, supplemented with 0.2 mg/mL colcemid (Roche, 
Basel, Switzerland) at 37 °C for 20 min, and subsequently 
washed three times with 2 mL PBS containing Ca2+ and 
Mg2+. A minimum of 15 colonies were collected in 2 mL 
1× trypsin-EDTA (Invitrogen) and incubated at 37 °C for 
5 min. The fi nal mixture of cells was pipetted several times 
to disaggregate the cells. The trypsin activity was stopped 
with 4 mL iPSC medium and cells were spun at 300 g 
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for 10 min. Subsequently, the pellet was resuspended and 
incubated in 1 mL pre-warmed potassium chloride solution 
(KCl, 0.075 M) for 10 min at 37 °C. Cells were then pre-
fi xed with 1 mL Carnoy fi xative solution (methanol/acetic 
acid = 3/1) at -20 °C, and immediately spun at 1800 rpm 
for 10 min. Finally, the supernatant was discarded, the 
pellet resuspended again in Carnoy fi xative solution and 
the cells were prepared for analysis.
RNA extraction, quantitative and non-quantitative 
real time polymerase chain reaction 
Total RNA was extracted from the cell lines, using the 
QIAGEN (Hilden, Germany) RNeasy MiniKit according to 
the manufacturer’s protocol (Invitrogen). RNA integrity and 
quantity were assessed with an Agilent (Santa Clara, CA, 
USA) 2100 bioanalyser, using RNA 6000 nanochips. 1 μg 
of total RNAs were reverse transcribed with the Superscript 
III reverse transcriptase (Invitrogen) according to the 
manufacturer’s protocol. One-twentieth cDNA template 
was used as template for each PCR reaction. cDNA was 
real time polymerase chain (PCR) amplifi ed in a 7900HT 
Sequence Detection Systems (Applied Biosystems, Foster 
City, CA, USA) using the Power SYBR Green PCR master 
mix (Applied Biosystems). Raw threshold-cycle (Ct) 
values were obtained with the Sequence Detection Systems 
2.0 software (Applied Biosystems). Melting curve analysis 
were automatically performed to monitor production of the 
appropriate PCR product. Relative quantities (RQs) were 
calculated with the formula RQ = E-Ct, using effi ciencies 
calculated for each run with the Data Analysis for Real-
quantitative PCR
Gene Forward Reverse Amplicon 
GUSB CCACCAGGGACCATCCAAT AGTCAAAATATGTGTTCTGGACAAAGTAA 79 
OCT3/4 
(POU5F1) AGTGCCCGAAACCCACACTG ACCACACTCGGACCACATCCT 81 
NANOG GATTTGTGGGCCTGAAGAAA TTGGGACTGGTGGAAGAATC 138 
LIN28 TGTAAGTGGTTCAACGTGCG CCTCACCCTCCTTCAAGCTC 145 
SOX2 GCGAACCATCTCTGTGGTCT GGAAAGTTGGGATCGAACAA 145 
Brachyury ACAGCTGTGACAGGTACCCAAC  CATGCAGGTGAGTTGTCAGAAT 109 
NKX2.5 CTATCCACGTGCCTACAGCGAC GCACAGCTCTTTCTTTTCGGC 67 
MSI TTGGGAAGGTGGACGACG CTCAAACGTGACAAACCCGAAC 80
FOXA2 GGAGCGGTGAAGATGGAAG TACGTGTTCATGCCGTTCAT 122
REX1 
(ZFP42) GAAGAGGCCTTCACTCTAGTAGTG TTTCTGGTGTCTTGTCTTTGCCCG 179
semi-quantitative PCR
Gene Forward Reverse Amplicon 
OCT3/4
(POU5F1) 
endogenous 
GCCTTCCTTCCCCATGGC CCTCAAAATCCTCTCGTTGT 911 
OCT3/4
(POU5F1) 
exogenous 
TCAAGCCTCAGACAGTGGTTC CCTCAAAATCCTCTCGTTGT 976 
NANOG 
endogenous TCCTCTATACTAACATGAGTG AACACAGTTCTGGTCTTCTG 319 
NANOG 
exogenous TCAAGCCTCAGACAGTGGTTC AACACAGTTCTGGTCTTCTG 385 
GAPDH AGCCACATCGCTCAGACACC GTACTCAGCGGCCAGCATCG 174 
DAZL ATGTTAGGATGGATGAAACTGAGATTA CCATGGAAATTTATCTGTGATTCTACT 178 
GDF3 AGACTTATGCTACGTAAAGGAGCT CTTTGATGGCAGACAGGTTAAAGTA 150 
KIT CAGGCAACGTTGACTATCAGT ATTCTCAGACTTGGGATAATC 288 
STELLAR GTTACTGGGCGGAGTTCGTA TGAAGTGGCTTGGTGTCTTG 174 
SOX2 F AGA TGC ACA ACT CGG AGA TC GTC ATG GAG TTG TAC TGC AG 438 
STEMCCA
OCT3/4 -KLF4
JUNCTION 
ACCATCTGTCGCTTCGAGGCC GGCTAGGAGGGCCGGGTTGTT 848 
Table 1. Primers used in the study.
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Time PCR (DART-PCR) algorithm, as described (Peirson 
et al., 2003). A mean quantity was calculated from triplicate 
PCR reactions for each sample, and this quantity was 
normalised to similarly measured quantity of normalisation 
gene (GusB). The highest normalised relative quantity 
was arbitrarily designated as a value of 1.0 and the other 
quantities were recalculated proportionally. Each PCR 
reaction was performed at least in triplicate with negative 
controls and the mean quantities were calculated from 
them. They were expressed as +/- SD. For non-quantitative 
PCR, reactions were performed in a Biometra  (Göttingen, 
Germany) thermocycler, with RedTaq polymerase mix 
(Sigma-Aldrich, St. Louis, MO, USA), 250 nM primers 
and 1 μL of cDNA. In the case of teratoma RT-PCR, we 
used 3 μL of template cDNA. Primers are listed in Table 1.
Bisulphite sequencing
About 2 μg of DNA, extracted from the iPSC and 
control cell lines, were bisulphite-converted and purifi ed 
using Epitect Bisulfite Kits (Qiagen) following the 
manufacturer’s instructions. DNA bisulphite treatment 
and processing were performed simultaneously for all cell 
lines. The promoter regions of OCT4 and NANOG were 
amplifi ed with specifi c primers as described previously 
(Freberg et al., 2007) using JumpStart REDTaq DNA 
Polymerase (Sigma-Aldrich) and KAPA2G Robust DNA 
Polymerase (Kapa Biosystems, Cambridge, MA, USA). 
Unincorporated primers and nucleotides were removed 
by incubation with Exonuclease I and Shrimp Alkaline 
Phosphatase (New England Biolabs, Ipswich, MA, USA), 
and the PCR products were cloned into the pCRII-TOPO 
vector (Invitrogen); transformants were grown on agar 
plates supplemented with X-Gal. Randomly chosen clones 
containing an insert were re-amplifi ed by M13 primers and 
sequenced by SP6 and T7 common primers from each cell 
line for each gene.
Teratoma formation assay
IPS cells were grown on Matrigel-coated dishes and 
collected by trypsin digestion. About 5x106 cells mixed 
with Matrigel (diluted in KO DMEM 5:1) were injected 
into the hind limb muscle of 8-week-old Nod-SCID mice. 
Teratomas were dissected after 8-12 weeks and fi xed in 4 
% paraformaldehyde overnight. Samples were embedded 
in paraffi n, cut, and stained with haematoxylin and eosin.
Affymetrix SNP 6.0 array and DNA copy number 
variations
Genotyping was carried out using the Affymetrix Genome-
Wide Human SNP Array 6.0 (San Diego, CA, USA). 
Labelling and hybridisation were performed following 
the protocols and kits provided by the manufacturer 
(Affymetrix Genome-Wide Human SNP Nsp/Sty Assay 
Kit 5.0/6.0). A set of 50 arrays previously hybridised and 
genotyped in the same laboratory was used as the copy 
number neutral reference sample. Copy-number variations 
(CNVs) and loss of heterozygosity (LOHs) were extracted 
with the Affymetrix proprietary Genotyping Console 
Software, using the standard setup recommended by the 
producer. Variations were annotated using the libraries 
supplied by Affymetrix (version 29). Copy number neutral 
LOH regions (UPDs) were detected by determining LOH 
regions from the genotype calls (dChip, https://sites.
google.com/site/dchipsoft/home, 2010) and by comparing 
the results with the ploidy detected in those regions by 
the Affymetrix software. Genes were annotated to detect 
variations using the Biomart database (http://www.biomart.
org/, 2010). Gene ontology analysis was performed in R 
(www.r-project.org, 2010) using the package GO_stats 
ver. 2.12. The gene’s universe was determined from the 
Affymetrix annotation fi les (version 29).
In vitro differentiation of the pluripotent stem cells
Whole iPSC and hESC colonies were dissected into ultra 
low attachment dishes (Corning Costar, Lowell, MA, 
USA) in KO DMEM medium supplemented with 10 % 
NCS, 1 mM L-glutamine, 100 μM non-essential amino 
acids, 100 μM 2-mercaptoethanol, 50 U/mL penicillin and 
50 mg/mL streptomycin (Gibco/Invitrogen). Within 24 h, 
cells aggregated to form embryoid bodies (EBs). Cardiac 
differentiation was performed using standard procedures, as 
previously described (Bettiol et al., 2006). Haematopoietic 
differentiation was carried out as recently described 
(Chicha et al., 2011). Briefly, collagenased colonies 
of iPSC were resuspended in StemPro-34 Serum-Free 
Media (Gibco/Invitrogen) supplemented with 0.5 ng/mL 
human recombinant BMP-4 (R&D Systems, Minneapolis, 
MN, USA) in low cluster tissue culture dishes (Corning 
Costar, Lowell, MA, USA). At day 1 of differentiation, 
embryoid bodies (EBs) were harvested and transferred to 
fresh StemPro media supplemented with 10 ng/mL BMP-4 
and 5 ng/mL bFGF. After 72 h, EBs were harvested again 
and transferred to a haematopoietic medium consisting 
of StemPro media supplemented with 100 ng/mL human 
recombinant VEGF (R&D Systems), 5 ng/mL bFGF, 100 
ng/mL SCF (Amgen), 100 ng/mL FLT3-L (Amgen), and 40 
ng/mL TPO (Peprotech, London, UK) for 4 additional days. 
All differentiation steps were performed under hypoxic 
conditions (5 % O2) in a humidifi ed incubator at 37 °C.
Flow cytometry
Cell suspensions were analysed after staining with 
antibodies specifi c for CD34 and KDR (BD Biosciences, 
Allschwill, Switzerland). Dead cells were identifi ed as 
7-aminoactinomycin D (7AAD)-positive cells and were 
excluded. Cells were stained in PBS containing 20 % 
human AB serum (Sigma-Aldrich) to prevent nonspecifi c 
binding. Data were collected using a FACS Calibur device 
(BD Biosciences) and analysed with Flowjo software 
(Treestar, Olten, Switzerland).
Immunoblotting
CHiPS A and CHiPS W cells were grown on Matrigel-
coated dishes, trypsinised and counted. Protein extracts 
were prepared by lysing the cells in protein isolation 
buffer (10 mM Tris-HCl pH 8, 1 % Triton-X100, 2 mM 
EDTA, 10 % glycerol, 137 mM NaCl, and a proteinase 
inhibitor cocktail) to a fi nal concentration of about 300,000 
cells per 15 μL. The lysates from 300,000 cells were 
resolved by SDS-polyacrylamide gel electrophoresis. For 
immunoblotting, the following antibodies were used: a 
p53-specifi c polyclonal antibody (Santa Cruz Laboratories, 
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sc-126), and a monoclonal p21-specifi c antibody (Santa 
Cruz Laboratories, sc-397). The experiment was repeated 
three times independently.
Results
Generation and characterisation of iPS cells from 
human fi broblasts
It has been demonstrated that the introduction of four 
reprogramming factors (OCT3/4, SOX2, NANOG, 
and LIN28) into a somatic cell results in a return to the 
pluripotent state, albeit with low effi ciency (Takahashi et 
al., 2007; Yu et al., 2007). Given that Nanog overexpression 
in mouse ESC increases reprogramming effi ciency (Silva 
et al., 2006), and that re-induction of the reprogramming 
transgenes leads to higher iPSCs generation (Maherali 
et al., 2008), we wanted to check whether two-step 
reprogramming would increase the effectiveness of the 
process. Therefore, human fi broblasts were reprogrammed 
to pluripotency fi rst by using only a NANOG-expressing 
lentiviral vector (Yu et al., 2007). After 24 h, one part of 
Fig. 1. Generation of induced pluripotent stem cell lines from human fi broblasts (A) Schematic representation 
of the reprogramming of the lines used in the study. Pur - puromycin. (B) Phase contrast images of the induced 
pluripotent stem cell lines CHiPS W and CHiPS A,  growing on feeders. Scale bar = 300 μm. (C) CHiPS W and 
CHiPS A karyotype. 
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the cells were re-transduced with three separate lentiviral 
vectors overexpressing the transcription factors OCT3/4, 
SOX2, and LIN28 (Yu et al., 2007), resulting in the 
CHiPS A line (Fig. 1A). The other part of the cells was 
treated with puromycin for 5 days before re-transduction 
with the same lentivectors as the CHiPS A line, resulting 
in the CHiPS W line (Fig. 1A). After three weeks, 
reprogrammed colonies were manually selected based on 
morphological criteria and expanded. The selected clones 
had typical ESC morphology (Fig. 1B) and displayed a 
normal karyotype as assessed by metaphase spreads (Fig. 
1C); however, the CHiPS A line proliferated signifi cantly 
Fig. 2. Characterisation of CHiPS W and CHiPS A lines. (A) Immunohistochemistry of pluripotency markers NANOG, 
OCT3/4, SSEA4, TRA1-60 (red) and DAPI (blue). NEG-negative control. Scale bar = 20 μm. (B) qRT-PCR analysis 
of Lin28, NANOG, SOX2, REX1 and OCT3/4 expression in parental fi broblasts, the human embryonic stem cell 
line H1 and the induced pluripotent stem cell lines CHiPS W and CHiPS A. (C) Bisulphite genomic sequencing of 
OCT4 and NANOG promoters in the CHiPS A, CHiPS W and H1 lines. Each row represents an individual sequencing 
reaction for a given amplicon. Open and fi lled circles indicate unmethylated and methylated CpGs dinucleotides, 
respectively. The percentage of methylation for each cell line is shown on the right. (D) RT-PCR analysis of exogenous 
and endogenous OCT3/4 and NANOG transcripts. HFF - human feeder fi broblasts.
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faster than the CHiPS W line (data not shown). The iPSC 
lines expressed the human ESC pluripotency antigens 
OCT3/4, NANOG, SSEA4 and TRA-1-60 as demonstrated 
by immunohistochemistry (Fig. 2A). We analysed the 
expression of pluripotency markers ZFP42 (REX1), SOX2, 
NANOG, LIN28, and OCT3/4 by quantitative PCR (Fig. 
2B). The analysis showed that, contrary to the CHiPS W 
line, the CHiPS A line did not express SOX2 and REX1 
but overexpressed OCT3/4 instead. In addition, the levels 
of LIN28 in the CHiPS A line were also higher than in 
the CHiPS W line. To clarify the origin of the transcript, 
we performed bisulphite sequencing, which revealed a 
surprising methylation status of the OCT3/4 and NANOG 
promoters in the CHiPS A and W lines (Fig. 2C). Despite 
overexpression of OCT3/4, the OCT3/4 promoter in the 
CHiPS A line was highly (55 %) methylated, while the 
NANOG promoter was demethylated. CHiPS W showed 
negligible methylation at the OCT3/4 promoter and 
moderate methylation at the NANOG promoter (Fig. 
2C). The results suggest a lack of retroviral silencing and 
therefore exogenous expression of OCT3/4 in the CHiPS A 
line. Semi-quantitative RT-PCR confi rmed the predominant 
Fig. 3. In vitro and in vivo differentiation of CHiPS W and CHiPS A lines. (A) Phase contrast images of CHiPS A, 
CHiPS W and hESC H1 lines after spontaneous differentiation as embryoid bodies in suspension culture, at day 0, 
4 and 8. Scale bar = 300 μm. (B) Quantitative expression of three germ layer markers in CHiPS A, CHiPS W and 
H1 lines. (C) Haematoxylin and eosin staining of tumours derived from intramuscular injection of iPSCs in NOD-
SCID mice. CHiPS W line formed teratoma with all embryonic germ layers mesoderm (cartilage) ectoderm (neural 
tissue) and endoderm (respiratory epithelium) whereas CHiPS A line formed germ cell-like tumour. The scale bar 
corresponds to 200 μm for CHiPS W, 100 μm for CHiPS A. (D) Expression of the seminoma (DAZL, GDF3, KIT, 
STELLAR) and the pluripotency (NANOG, OCT3/4) markers in CHiPS A-derived tumour by RT-PCR.
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expression of exogenous OCT3/4 and NANOG in the 
CHiPS A line, along with endogenous genes (Fig. 2D). 
At the same time low levels of endogenous NANOG 
expression in CHiPS A line, despite complete promoter 
demethylation suggest other mechanisms blocking gene 
expression.
Differentiation potential of CHiPS A
The CHiPS A line, despite its ES-like morphology, failed 
to differentiate in vitro (Fig. 3A). During differentiation 
via embryoid bodies (EBs), in contrast to the CHiPS 
W line and the control hESC H1 line, EBs of CHiPS A 
dissociated over time (Fig. 3A). We also tried to direct 
differentiation of CHiPS A under adherent conditions using 
10 μM all-trans retinoic acid or to induce differentiation 
on a Matrigel-coated dish by bFGF withdrawal. However, 
we were unable to obtain mature EBs and cells ultimately 
dissociated over time (data not shown). To investigate 
the differentiation commitment to the three embryonic 
germ layers, we analysed the acquired expression of 
FOXA2 (endoderm), MSI1 (ectoderm), and Brachyury 
(mesoderm) marker genes within the EBs of CHiPS A and 
CHiPS W from day 0 to day 8 (Fig. 3B). We observed the 
expected change in all the markers analysed in the CHiPS 
W and hESC H1 lines, indicating proper differentiation 
commitment. However, none of the markers increased with 
time in the CHiPS A line (Fig. 3B). We decided to verify 
whether this disability regarding in vitro differentiation 
extended into a defect in an in vivo teratoma formation 
assay. The histological examination showed that the 
CHiPS A cells formed invasive (multiple infi ltrations into 
the surrounding tissue, lack of defi ned borders) germ cell-
like tumours when injected into NOD-SCID mice (Fig. 
3C). In the same assay, the CHiPS W cells formed benign 
teratomas, as expected (Fig. 3C). To confi rm the germ 
cell-like nature of the CHiPS A tumour, we also verifi ed 
the expression of known seminoma markers DAZL, GDF3, 
KIT, and STELLAR, as well as the pluripotency markers 
NANOG, OCT3/4, and SOX2 (Ezeh et al., 2005; Gopalan 
et al., 2009) (Fig. 3D). We observed strong endogenous 
Fig. 4. Analysis of the CHiPS A-derived tumour. (A) Expression of CD117 (or KIT, a germ cell tumour marker). (B) 
Expression of CD99 (a primitive neuroectodermal tumours and sex cord stromal tumours marker). (C) Increased 
proliferation in CHiPS A-derived tumour, as compared to CHiPS W- and H1-derived teratomas, indicated by Ki-67 
staining. NEG-negative control with CHiPS A-derived tumour. Scale bar = 100 μm.
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and exogenous NANOG expression as well as GDF3 
and STELLAR.  DAZL and KIT were weakly expressed 
(Fig. 3D). However, KIT gave a very strong signal in the 
immunohistochemical assessment of the CHIPS A-derived 
tumor (Fig. 4A) as well as CD99, a known marker of 
primitive neuroectodermal and sex cord stromal tumours 
(Fig. 4B). In line with commonly increased proliferation in 
tumours (Soini et al., 1998), the CHiPS A-derived tumours 
showed a higher proliferative index compared to the CHiPS 
W- and H1-derived teratomas (Fig. 4C).
 To investigate whether priming the cells with 
NANOG could have activated the carcinogenic program 
during reprogramming, regardless of the choice of other 
reprogramming genes, we repeated human fibroblast 
reprogramming, fi rst with NANOG and then with the set 
of four Yamanaka reprogramming factors (OCT3/4, SOX2, 
MYC, KLF4) expressed from one polycistronic vector 
(Sommer et al., 2009). The resulting iPSC line, the CHiPS 
22, also failed to differentiate in vitro. Importantly, in the 
teratoma formation assay, the CHiPS 22 cells gave rise 
to germ cell-like tumours, as did the CHiPS A cells (Fig. 
5A). Semi-quantitative RT-PCR analysis of pluripotency 
gene expression showed that similarly to the CHiPS A line, 
transgenes for OCT3/4 and NANOG were not silenced, 
however, the relative quantities of the endogenous versus 
exogenous transcripts resembled those of the CHiPS 
W (Fig. 5B). Similar to the CHiPS W and by contrast 
to the CHiPS A, the OCT3/4 promoter of the CHiPS 
22 was found hypomethylated (Fig. 5C). Therefore, we 
conclude that priming cells with NANOG before complete 
reprogramming might result in a germ cell-like tumour 
phenotype in vivo, regardless of the reprogramming factors 
used.
Molecular characterisation 
It has been previously demonstrated that genomic 
abnormalities in hESC might lead to neoplastic progression 
(Werbowetski-Ogilvie et al., 2009). To investigate the 
Fig. 5. Characterisation of CHiPS 22 line. (A) Haematoxylin and eosin staining of germ cell-like tumour derived 
from CHiPS 22 cells. Scale bar = 100 μm. (B) Expression of endogenous and exogenous OCT3/4 and NANOG in 
CHiPS 22 line by RT-PCR. Exogenous NANOG is expressed from two constructs, indicated by NANOG exo and STE 
(Stemcca). (C) Bisulphite genomic sequencing of OCT4 and NANOG promoters in CHiPS 22 and H1 lines. Each 
row represents an individual sequencing reaction for a given amplicon. Open and fi lled circles equal unmethylated 
and methylated CpGs dinucleotides, respectively. Percentage of methylation for each cell line is shown on the right.
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origin of the oncogenic potential of the CHiPS A line, 
array comparative genomic hybridisation (aCGH) was 
performed to evaluate the presence of genomic signatures. 
We compared the CHiPS A and CHiPS W lines with four 
hESC lines. This revealed some chromosomal variations, 
which were not detected previously with G banding. 
Surprisingly, the total observed abnormalities were minor, 
compared to the ESC lines (Fig. 6A,B). Detailed analysis 
of each chromosome showed that the gains and losses 
were mainly concentrated in chromosomes 1, 3, 14, 16, 
21, 22, and X for CHiPS A and 3, 16, and X for CHiPS W 
(Fig. 6D). There were also multiple uniparental disomies 
affecting chromosomes 1, 2, 4, 5, 6, 7, 8, 9, 10, 12, and 
18 in both lines in the same manner, suggesting a parental 
origin. Surprisingly, thorough examination revealed only 
a few genes present in the affected regions (Fig. 6C). Of 
these, 26 differed between the CHiPS A and the CHiPS W 
lines, 10 in the deleted regions and 16 in duplicated regions 
(Fig. 6E). Those genes were CHiPS A-specifi c, since 
they were also absent, apart from the olfactory receptor 
OR11H12, from the mutated regions of the control hESC 
line (HS401) (Table 2). Unexpectedly, the genes did not 
Fig. 6. Chromosomal variations in CHiPS A and CHiPS W lines. (A) Total number of variations, (B) genomic coverage 
of the variations and (C) total number of mutated genes. H1, HS293, HS401, SVF02 – human embryonic stem cell 
lines, HFF – human feeder fi broblasts. (D) Per chromosome coverage of genomic variations and (E) the number of 
genes in either deleted, duplicated or UPDs (uniparental disomies) regions in CHiPS A, CHiPS W and ES401 lines. 
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include any tumour suppressor genes or oncogenes, nor 
did they encompass any known pluripotency genes (Table 
2). The gene ontology analysis performed for three classes 
(Gene Ontology Molecular Function (GOMF), Biological 
Processes (GOBP) and Kegg pathways) showed multiple 
differences between the two lines, as summarised in Table 
3. Of particular interest were potential defects in the cardiac 
and haematopoietic differentiation pathways in the CHiPS 
A line, as also revealed in the comparative pathway analysis 
between the CHiPS A and HS401 lines (Table 4).
 To evaluate the prognostic values of aCGH analysis, 
we investigated whether the cells were capable of cardiac 
and directed haematopoietic differentiation in vitro, via 
embryoid body formation. In line with the aCGH data, 
quantitative analysis of the expression of the TBX1/
Brachyury, a major regulator of cardiac mesoderm 
formation, and NKX2-5, a cardiopoietic marker, revealed 
their absence from the CHiPS A line during in vitro 
cardiac differentiation (Fig. 7A). Further differentiation 
led to beating cardiomyocytes in case of the CHiPS W 
(Chicha et al., 2011), but not in the CHiPS A, which 
failed to differentiate and dissociated over time. It has 
been previously shown that the CHiPS W line is capable 
of undergoing haematopoietic differentiation (Chicha et 
al., 2011). FACS analysis of differentiating embryoid 
bodies from the CHiPS W and the hESC H1 line showed 
an increase in the CD34+/KDR+ cell population with 
differentiation time; however, these vascular endothelial 
surface antigen markers were absent from the CHiPS A 
line (Fig. 7B).
 The TP53 (p53) tumour suppressor is an established 
factor connecting tumourigenesis and reprogramming 
to pluripotency, (reviewed in Tapia and Scholer, 2010). 
Therefore, we analysed p53 and p21 protein levels in the 
CHiPS A and CHiPS W cell lines. In the normal, pluripotent 
CHiPS W cell line, the proportion of p53 to p21 was higher 
than in the tumourigenic CHiPS A cell line (Fig. 7C).
Discussion
Embryonic stem cells (ESCs) and induced pluripotent stem 
cells (iPSCs) offer great therapeutic promise. However, 
their potential tumourigenicity must be addressed before 
they can be taken into the clinic. In 1997, Bonnet and Dick 
proposed the new concept of cancer stem cells (CSCs) 
(Bonnet and Dick, 1997), a small selected population 
within a tumour, characterised by stem-like genomic and 
epigenetic signatures, including for instance OCT3/4 
and NANOG expression. It is still unclear where CSCs 
originate, but reprogramming and carcinogenesis share 
many common features. For instance, deactivation of the 
antitumour p53-p21 barrier increases the yield of iPSC 
generation (Hong et al., 2009). For the therapeutic use 
of stem cells in the future, it is of crucial importance 
to discriminate between normal and cancer stem cells; 
however, proper cellular models are still missing. 
Fig. 7. Analysis of cardiac and haematopoietic differentiation, as well as p53 and p21 expression in CHiPS A and 
CHiPS W lines. (A) Differential quantitative expression of cardiac markers Brachyury and NKX2.5 at day 0, 4 
and 8 of cardiac differentiation in CHiPS A, CHiPS W and H1 lines. (B) FACS analysis of the expression of the 
haematopoietic markers KDR and CD34 at day 0, 4 and 8 of haematopoietic differentiation. (C) Protein levels of 
p53 and p21 in CHiPS A and CHiPS W assessed by western blot, GAPDH – loading control.
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 In the present work, we generated two reprogrammed 
cell lines from human dermal fi broblasts. The fi rst line, 
CHiPS W, had a differentiation potential comparable to a 
normal human ESC line while the other, CHiPS A, failed 
to undergo in vitro and in vivo differentiation and induced 
germ cell-like tumours, confi rmed by marker expression 
analysis. We sought to characterise genomic variations 
at the genome-wide level and to associate these with the 
behaviour of the cell lines used in this study. G-banding 
was used to assess variations at the macroscopic level and, 
subsequently, Affymetrix SNP6.0 arrays were run to detect 
copy number variations (CNVs) at kb resolution. On this 
scale, no variations were detected that could be associated 
with tumour suppressor or oncogenes. Although a number 
of common structural variants, like InDels or short 
inversions, escape the methods used in this study, CNVs 
represent the predominant form of variation, and have the 
highest de novo mutation rate in the genome. Our results 
suggest that the role of genomic variations in determining 
the tumourigenic phenotype might not be a major one, 
which implies epigenetic-level mechanisms leading 
to tumourigenic characteristics. However, considering 
multiple reports of iPSCs genomic instability (Gore et al., 
2011; Hussein et al., 2011; Laurent et al., 2011; Mayshar 
et al., 2010; Pasi et al., 2011), it remains an open question 
whether the genomes of the derived cell lines remain stable 
over time.
 The p53 tumour suppressor plays a pivotal role in 
cancer prevention (reviewed in Molchadsky et al., 2010) 
but also, as recently demonstrated, in reprogramming 
somatic cells to pluripotency (Hong et al., 2009; Kawamura 
et al., 2009; Utikal et al., 2009). Recent microRNA 
profi ling analysis of iPSCs and cancer cell lines also 
demonstrated differences in the status of the p53 network 
in these two cellular populations (Neveu et al., 2010). 
Morigucchi et al. have proposed that a higher ratio of p53 
to p21 might be responsible for shifting the balance from 
stemness to tumourigenicity in iPSCs (Moriguchi et al., 
CHiPS A but not CHiPS W CHiPS W but not CHiPS A CHiPS A but not HS401 
WDR63 ZDHHC11 WDR63
MCOLN3 BRD9 MCOLN3
SYDE2 FAM115A SYDE2
GJA5 OR2F2 GJA5
GJA8 OR2F1 GJA8
GPR89B OR2Q1P GPR89B
NR5A2 PAOX NR5A2
FAM58B PCDH11X FAM58B
GATA2 GATA2
OR11H12 C3orf27
NF1L6 RPN1
NF1L4 TMED10P2
TMPRSS15 MIR720
PPIAL3 UGT2B28
EFCAB6 RBPJP6
SULT4A1 ATP5A1P6
PNPLA5 MTG1
HMGN2L9 CYP2E1
SPRN
STX2
RAN
NF1L6
NF1L4
TMPRSS15
PPIAL3
EFCAB6
SULT4A1
PNPLA5
HMGN2L9
ZNF81
ZNF182
ZNF630
SPACA5
Table 2. List of the genes in the affected regions characteristic for a given line.
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2010). Our results do not support the model proposed by 
Moriguchi, as the ratio of p53 to p21 was lower in the 
tumourigenic CHiPS A line than in the CHiPS W line. 
The lack of differentiation within the CHiPS A-derived 
teratomas resembles tumours derived with p53-defi cient 
iPSCs, using the four Yamanaka factors (Hong et al., 2009). 
Accordingly, we observed lower p53 protein expression in 
our tumourigenic line CHiPS A, compared to the CHiPS 
W. This is in accordance with the crucial role of p53 in 
limiting tumourigenicity. At the same time, the p53/p21 
ratio in the CHiPS 22 line, contrary to the CHiPS A, was 
similar to the CHiPS W, suggesting that other mechanisms 
are involved (data not shown).
 At this stage of investigation, we can only speculate on 
the possible molecular mechanism leading to the observed 
phenotype. Reprogramming of somatic cells into the 
CHiPS A and CHiPS W lines was achieved by initial pre-
transduction with NANOG. A recent report by Tiemann et 
al. shows the importance of the stoichiometry of RGs in the 
reprogramming process (Tiemann et al., 2011). It remains 
to be determined if the pre-selection with puromycin in the 
CHiPS W line signifi cantly changed the fi nal stoichiometry 
of the RGs, allowing better reprogramming into a stable 
pluripotent state as compared to the CHiPS A and CHiPS22 
lines. Considering the Tiemann et al. data, it is plausible 
that a distinct stoichiometry of RGs controls not only 
full reprogramming, but also the balance between the 
pluripotent and tumourigenic phenotypes.
 Although NANOG is not considered to be cancer 
inducing, it might have pre-induced the cell to additional 
embryonic heart tube development 
positive regulation of phagocytosis 
cell-cell junction assembly
embryonic placenta development 
lens development in camera-type eye
blood vessel development 
pituitary gland development
positive regulation of angiogenesis 
cell fate determination 
embryonic development 
positive regulation of specifi c transcription from RNA polymerase II promoter
regulation of endocytosis
cell junction organization 
cell maturation
embryonic limb morphogenesis
appendage morphogenesis 
limb development 
RNA polymerase II transcription factor activity  enhancer binding 
channel activity
scavenger receptor activity
steroid hormone receptor activity
sulfotransferase activity
sequence-specifi c DNA binding
Maturity onset diabetes of the young
Table 3. Process affected in CHiPS A as compared to CHiPS W.
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Table 4. Process affected in CHiPS A as compared to HS401.
cell separation during cytokinesis
microvillus assembly
embryonic heart tube development 
protein amino acid N-linked glycosylation via asparagine
positive regulation of phagocytosis
drug metabolic process
cell-cell junction assembly
digestive system development
gut morphogenesis
mitotic spindle organization 
acrosome reaction
embryonic placenta development
lens development in camera-type eye
pituitary gland development 
plasma membrane fusion
positive regulation of angiogenesis 
protein export from nucleus
blood vessel development 
xenobiotic metabolic process
RNA export from nucleus
cell fate determination
androgen receptor signaling pathway
positive regulation of specifi c transcription from RNA polymerase II promoter
cytokinesis
regulation of endocytosis
dolichyl-diphosphooligosaccharide-protein glycotransferase activity 
calcium-dependent protein binding 
SNAP receptor activity
SNARE binding
glucuronosyltransferase activity  transferring glycosyl groups
transferase activity
androgen receptor binding
oxidoreductase activity acting on paired donors  with incorporation or reduction of molecular oxygen
oxidoreductase activity  acting on paired donors  with incorporation or reduction of molecular oxygen
RNA polymerase II transcription factor activity  enhancer binding
oxygen binding
transcription regulator activity 
scavenger receptor activity
steroid hormone receptor activity
Metabolism of xenobiotics by cytochrome P450
Drug metabolism - cytochrome P450
Pentose and glucuronate interconversions
Ascorbate and aldarate metabolism
Maturity onset diabetes of the young
Linoleic acid metabolism
SNARE interactions in vesicular transport
Porphyrin and chlorophyll metabolism
N-Glycan biosynthesis
Androgen and estrogen metabolism
Starch and sucrose metabolism 
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cancer pathway-activating changes. Considering that 
CHiPS 22, another iPSC line with similar characteristics, 
could be obtained using a different set of reprogramming 
factors but with the same pre-induction with NANOG, 
the molecular mechanism behind the process is probably 
NANOG-related. While it is known that NANOG 
expression suppresses differentiation in murine ESCs 
(Chambers et al., 2003), a recent loss-of-function analysis 
in cancer cell lines has demonstrated a role of NANOG 
in tumour development (Jeter et al., 2009). In addition, 
Lindgren et al. have shown that failed repression of 
Nanog in Pten null mouse ESCs leads to tumour initiation 
(Lindgren et al., 2011). In germ cell tumours and derived 
cell lines, methylation of CpGs in the NANOG promoter has 
been correlated with the differentiation state (Nettersheim 
et al., 2011). Consequently, the lack of silencing of 
endogenous and/or exogenous NANOG expression during 
the CHiPS A and the CHiPS 22 differentiation in vitro 
and in the tumours might be directly responsible for the 
observed phenotype. Whether pre-induction of fi broblasts 
with NANOG carried by excisable factors or other transient 
means would result in the same cellular phenotype remains 
to be determined.
 We believe that the resulting phenotype is an outcome 
of complex and interrelated epigenetic changes. The 
role of NANOG seems to be crucial; however, CHiPS 
A and CHiPS 22 differ despite their similar phenotypes. 
For instance, the CHiPS A line lacks SOX2 expression. 
Nevertheless the re-introduction of SOX2 using a lentiviral 
vector did not rescue the phenotype and the new SOX2+ /
CHiPS A line still failed to differentiate (data not shown). 
Furthermore, the tumourigenic CHiPS 22 line expresses 
SOX2, which altogether suggests that the molecular 
mechanism is not SOX2-dependent. Similarly, the CHiPS 
A line, in contrast to the CHiPS 22, overexpresses OCT3/4 
and, as previously demonstrated, ectopic expression of 
OCT3/4 might block progenitor differentiation and cause 
carcinogenesis (Hochedlinger et al., 2005). Likewise, 
human cancers often display altered expression of MYC, 
a proto-oncogene used here during the reprogramming of 
the CHiPS 22 line. It has also been demonstrated during 
reprogramming that the MYC oncogene leads to increased 
tumour transformation (Okita et al., 2007). However, 
the CHiPS A was reprogrammed with the Thomson set 
of reprogramming genes, and its MYC expression was 
barely stimulated (data not shown), indicating that MYC 
is not directly responsible for the resulting carcinogenic 
behaviour.
Conclusion and Summary
The present data highlight fi ve major points: priming with 
NANOG before reprogramming of human somatic cells can 
generate cells with the characteristics of iPS cells; despite 
their expression of pluripotency markers, such cell lines 
may fail to differentiate; in vitro differentiation failure 
might translate into germ cell-like tumour induction in 
the in vivo differentiation assay; the tumourigenic iPSC 
line might be genetically stable which implicates the 
involvement of epigenetic mechanisms in the activation of 
the carcinogenic program; one of the plausible mechanisms 
of carcinogenic program induction may involve the p21/
p53 ratio.
 Our results are the fi rst describing iPSC lines that 
behave similarly to pluripotent cell lines in vitro but 
are unable to differentiate. These cells do however 
induce germ cell-like tumours in vivo. The tumourigenic 
character of the reprogrammed lines might result from 
epigenetic events that occurred during priming the cells 
with NANOG. It is therefore important to test derived 
iPSCs, not only at the molecular and cellular level, but 
also using an in vivo teratoma formation assay, which is 
essential in the assessment of the carcinogenic potential 
of the reprogrammed pluripotent stem cells. At the same 
time, we believe that our results might open new vistas 
in the area of stemness versus carcinogenesis, while the 
CHiPS A, CHiPS 22 and CHiPS W lines might serve as a 
model for comparing cellular signalling leading to normal 
and malignant conditions.
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Discussion with Reviewers
Reviewer I: Do the authors think that more epigenetic 
studies should be done?
Authors: Considering the increasing amount of data 
connecting tumourigenicity and epigenetic mechanisms 
it would be very interesting to investigate not only the 
genomics but also epigenomics of the generated lines. 
This would be particularly relevant in the context of 
NANOG but also the genes already known to participate 
in the processes of reprogramming. We believe that this 
kind of investigation if applied on the parental fi broblasts 
together with the “normal” and “tumourigenic” lines that 
we have generated, could provide interesting data on the 
mechanisms leading to malignancy.
